Phenotype
|
Fish
|
Conditions
|
Figures
|
cardiac ventricle septin15 expression absent, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2017
|
pronephros morphogenesis decreased process quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2 ,
Fig. 3
from Dash et al., 2014
|
muscle muscle tendon junction septin15 expression absent, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2017
|
lateral plate mesoderm bilateral symmetry, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2014
|
cilium assembly decreased process quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2014
|
pronephric tubule ciliary basal body disorganized, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2014
|
heart contraction decreased rate, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2017
|
whole organism pck1 expression increased amount, abnormal
|
WT + MO1-septin15
|
control
|
Fig. 8
from Dash et al., 2016
|
whole organism ascl1b expression increased amount, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 6
from Dash et al., 2016
|
heart contraction decreased process quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 5,
Fig. 7
from Dash et al., 2017
|
heart striated muscle thin filament Ab2-actc1 labeling decreased amount, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 4
from Dash et al., 2017
|
embryonic heart tube left/right pattern formation decreased process quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2014
|
whole organism glucose homeostasis decreased process quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 8
from Dash et al., 2016
|
pronephric tubule motile cilium disoriented, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2014
|
pronephric podocyte lacks parts or has fewer parts of type pronephric podocyte slit diaphragm, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2014
|
Kupffer's vesicle motile cilium decreased length, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2014
|
pronephric capsular space dilated, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2014
|
endoderm shha expression absent, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 6
from Dash et al., 2016
|
pronephros cystic, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2014
|
heart contraction decreased process quality, abnormal
|
WT + MO1-septin15
|
chemical treatment: 4-(diethylamino)benzaldehyde
|
Fig. 8
from Dash et al., 2017
|
ependymal cell cilium disoriented, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2014
|
heart Z disc structure, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2017
|
whole organism glucose increased amount, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 8
from Dash et al., 2016
|
heart tube bilateral symmetry, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2014
|
heart striated muscle thin filament disorganized, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2017
|
exocrine pancreas decreased length, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 4
from Dash et al., 2016
|
pronephric tubule apical part of cell physical object quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 6
from Dash et al., 2014
|
pronephric podocyte apical part of cell malformed, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2014
|
renal water transport decreased process quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 4
from Dash et al., 2014
|
glomerular filtration decreased process quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 4
from Dash et al., 2014
|
post-vent region curved, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2014
|
whole organism ins expression decreased amount, abnormal
|
WT + MO1-septin15
|
chemical treatment by environment: glucose
|
Fig. 8
from Dash et al., 2016
|
heart contraction process quality, abnormal
|
WT + MO1-septin15
|
chemical treatment: retinoic acid
|
Fig. 7
from Dash et al., 2017
|
pronephric tubule actin cytoskeleton decreased object quality, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 6
from Dash et al., 2014
|
heart septin15 expression absent, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2017
|
cardiac ventricle decreased size, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2,
Fig. 5
from Dash et al., 2017
|
whole organism notch1b expression decreased amount, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 6
from Dash et al., 2016
|
brain hydrocephalic, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2014
|
ependymal cell cilium decreased length, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2014
|
heart aldh1a2 expression decreased amount, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2017
|
whole organism pck1 expression increased amount, abnormal
|
WT + MO1-septin15
|
chemical treatment by environment: glucose
|
Fig. 8
from Dash et al., 2016
|
heart striated muscle myosin thick filament disorganized, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2017
|
heart contraction process quality, abnormal
|
WT + MO1-septin15
|
control
|
Fig. 7
from Dash et al., 2017
|
heart edematous, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2014
|
heart morphology, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2017
|
pancreatic B cell cell population proliferation decreased occurrence, abnormal
|
WT + MO1-septin15
|
control
|
Fig. 2
from Dash et al., 2016
|
central canal has fewer parts of type ependymal cell cilium, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2014
|
whole organism anterior region aldh1a2 expression decreased amount, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 7
from Dash et al., 2017
|
whole organism glucose homeostasis decreased process quality, abnormal
|
WT + MO1-septin15
|
chemical treatment by environment: glucose
|
Fig. 8
from Dash et al., 2016
|
heart looping decreased occurrence, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2,
Fig. 5
from Dash et al., 2017
|
pronephric podocyte cell projection malformed, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2014
|
heart contraction increased process quality, abnormal
|
WT + MO1-septin15
|
chemical treatment: retinoic acid
|
Fig. 7
from Dash et al., 2017
|
endocrine pancreas has fewer parts of type pancreatic B cell, abnormal
|
WT + MO1-septin15
|
control
|
Fig. 2
from Dash et al., 2016
|
pronephric tubule dilated, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2 ,
Fig. 3
from Dash et al., 2014
|
whole organism notch1a expression decreased amount, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 6
from Dash et al., 2016
|
heart cardiac myofibril disorganized, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2,
Fig. 3
from Dash et al., 2017
|
pronephric tubule increased diameter, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2014
|
heart Z disc absent, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2017
|
pronephric tubule has fewer parts of type pronephric tubule microvillus, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2014
|
yolk edematous, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2014
|
atrium elongated, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 2
from Dash et al., 2017
|
whole organism ins expression decreased amount, abnormal
|
WT + MO1-septin15
|
control
|
Fig. 8
from Dash et al., 2016
|
heart Z disc disorganized, abnormal
|
WT + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2017
|
endocrine pancreas has fewer parts of type pancreatic A cell, abnormal
|
ia1Tg + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2016
|
pancreas pancreatic A cell differentiation decreased occurrence, abnormal
|
ia1Tg + MO1-septin15
|
standard conditions
|
Fig. 3
from Dash et al., 2016
|
exocrine pancreas development decreased process quality, abnormal
|
jh1Tg + MO1-septin15
|
standard conditions
|
Fig. 4
from Dash et al., 2016
|
islet cell differentiation decreased process quality, abnormal
|
jh1Tg + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2016
|
exocrine pancreas malformed, abnormal
|
jh1Tg + MO1-septin15
|
standard conditions
|
Fig. 4
from Dash et al., 2016
|
pronephric tubule motile cilium decreased length, abnormal
|
li1Tg + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2014
|
cilium assembly decreased process quality, abnormal
|
li1Tg + MO1-septin15
|
standard conditions
|
Fig. 5
from Dash et al., 2014
|
gut epithelium EGFP expression mislocalised, abnormal
|
nl1Tg + MO1-septin15
|
chemical treatment by environment: DAPT
|
Fig. 7
from Dash et al., 2016
|
endocrine pancreas development decreased process quality, abnormal
|
nl1Tg + MO1-septin15
|
chemical treatment by environment: DAPT
|
Fig. 7
from Dash et al., 2016
|
intrapancreatic duct ins expression mislocalised, abnormal
|
nl1Tg + MO1-septin15
|
control
|
Fig. 7
from Dash et al., 2016
|
exocrine pancreas EGFP expression mislocalised, abnormal
|
nl1Tg + MO1-septin15
|
control
|
Fig. 7
from Dash et al., 2016
|
intrapancreatic duct EGFP expression mislocalised, abnormal
|
nl1Tg + MO1-septin15
|
control
|
Fig. 7
from Dash et al., 2016
|
gut epithelium ins expression mislocalised, abnormal
|
nl1Tg + MO1-septin15
|
control
|
Fig. 7
from Dash et al., 2016
|
endocrine pancreas development decreased process quality, abnormal
|
nl1Tg + MO1-septin15
|
control
|
Fig. 7
from Dash et al., 2016
|
gut epithelium EGFP expression mislocalised, abnormal
|
nl1Tg + MO1-septin15
|
control
|
Fig. 7
from Dash et al., 2016
|
exocrine pancreas EGFP expression mislocalised, abnormal
|
nl1Tg + MO1-septin15
|
chemical treatment by environment: DAPT
|
Fig. 7
from Dash et al., 2016
|